CagriSema (cagrilintide + semaglutide combination)
Fixed-ratio combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist)
At a glance
What it is: Fixed-ratio combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist).
Primary research applications:
- Obesity (Phase 3)
- Type 2 diabetes (Phase 3)
Editorial summary: CagriSema combines two complementary appetite-regulating mechanisms. The Phase 3 REDEFINE results, while positive, underwhelmed vs. high Phase 1b expectations — closer to tirzepatide than expected to exceed it.
What is CagriSema?
CagriSema is Novo Nordisk's fixed-ratio combination of cagrilintide (a long-acting amylin analog) and semaglutide (the GLP-1 agonist behind Ozempic/Wegovy). The rationale: amylin and GLP-1 signal satiety through separate brainstem and hypothalamic pathways, so combining them should produce additive effects.[1]
Mechanism of action
Semaglutide acts on GLP-1 receptors in the hypothalamus and brainstem; cagrilintide acts on amylin/calcitonin receptors primarily in the area postrema and nucleus tractus solitarius. The combined signal produces greater appetite suppression than either alone and — in principle — may allow each component to be dosed lower for better tolerability.
What the research shows
The peer-reviewed literature on CagriSema is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Produces larger weight loss than semaglutide alone | REDEFINE 1 confirmed | Supported |
| Beats tirzepatide in head-to-head | No direct comparison; cross-trial suggests similar magnitude | Uncertain |
| Better tolerability than equivalent-potency GLP-1 monotherapy | Preliminary; confirmation awaited | Plausible |
Reported user experiences
How the research describes administration
Administered as a fixed-ratio once-weekly subcutaneous injection in Phase 3 trials. Not yet approved for clinical use.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
CagriSema is likely to be a useful addition to the obesity pharmacologic toolkit when approved, but the idea that it would definitively beat the incretin triple-agonists (retatrutide) has been tempered. It occupies a similar efficacy tier to tirzepatide based on current Phase 3 data.
Frequently asked questions
What are the components of CagriSema?
Cagrilintide (a long-acting amylin analog) and semaglutide (a long-acting GLP-1 agonist). The 'cagri' and 'sema' halves are combined in a fixed-ratio once-weekly injection.
Is CagriSema better than tirzepatide?
Cross-trial comparisons suggest they're in similar territory for weight loss (~20–22%). No head-to-head has been run.
Why was the market reaction to REDEFINE 1 negative?
The Phase 1b data had generated expectations that CagriSema would produce substantially larger weight loss than tirzepatide. Phase 3 showed strong but not category-redefining results, which disappointed markets that had already priced in bigger numbers.
Is CagriSema approved?
Not as of early 2026. Novo Nordisk has indicated regulatory submissions based on REDEFINE data.
References
- Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4 mg with once-weekly semaglutide 2.4 mg in type 2 diabetes. Lancet. 2023;402:720-730. https://pubmed.ncbi.nlm.nih.gov/37364589/
- Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg. Lancet. 2021;397:1736-1748. https://pubmed.ncbi.nlm.nih.gov/33894838/
- Novo Nordisk. REDEFINE 1 trial results (corporate release / preliminary Phase 3 reporting). Primary publication pending in a peer-reviewed journal. https://pubmed.ncbi.nlm.nih.gov/?term=CagriSema+REDEFINE